Organogenesis Hldgs Q3 2024 Adj. EPS $0.10 Beats $(0.01) Estimate, Sales $115.177M Beat $108.833M Estimate
Organogenesis Hldgs Q3 2024 Adj. EPS $0.10 Beats $(0.01) Estimate, Sales $115.177M Beat $108.833M Estimate
Organogenesis控股2024年第三季調整每股收益$0.10,超過$(0.01)的預期,銷售額11517.7萬美元,超出預期的10883.3萬美元。
Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $(0.01) by 1100 percent. This is a 150 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $115.177 million which beat the analyst consensus estimate of $108.833 million by 5.83 percent. This is a 6.12 percent increase over sales of $108.530 million the same period last year.
Organogenesis控股(納斯達克:ORGO)報告每股盈利爲0.10美元,超過分析師共識估計的(0.01)美元1100%。這比去年同期每股盈利0.04美元增長150%。公司報告的季度銷售額爲11517.7萬美元,超過分析師共識估計的10883.3萬美元5.83%。這比去年同期的10853萬美元銷售額增長6.12%。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。